Danny Hsu: Fascinating Insight into the Cellular Mechanisms of Statins in APLS
Danny Hsu, President of THANZ, reposted from Journal of Thrombosis and Haemostasis (JTH) on LinkedIn:
”Fascinating insight into the cellular mechanisms of statins in APLS.”
Quoting Journal of Thrombosis and Haemostasis (JTH)‘s post:
”Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies
By Dominika Marova, Paul Frankenbach, Dr. Anne Hollerbach, Susanne Strand, Wolfram Ruf, Karl Lackner, and Nadine Müller Calleja
Antiphospholipid antibodies (aPLs) drive thrombosis and inflammation via endothelial protein C-receptor (EPCR)–mediated binding of lysobisphosphatidic acid (LBPA).
Statins may exert direct anti-APS effects through molecular competition at EPCR–lipid interfaces, not merely via lipid-lowering or pleiotropic vascular actions.”
Read the full article here.
Article: Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies
Authors: Dominika Marova, Paul Frankenbach, Anne Hollerbach, Susanne Strand, Wolfram Ruf, Karl J. Lackner, Nadine Müller-Calleja
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria